Palisade Bio Inc (PALI) FinancialsPALIPalisade Bio Inc

Evaluating the bottom line, Palisade Bio Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -2339.60%, while the net margin is -2114.80%. These profitability ratios, combined with a Return on Equity (ROE) of -51.37%, provide a clear picture of how effectively PALI converts its operational activities into shareholder value.

In the context of the broader market, PALI competes directly with industry leaders such as STRO and ABEO. With a market capitalization of $372.94M, it holds a leading position in the sector. When comparing efficiency, PALI's gross margin of 100.00% stands against STRO's 100.00% and ABEO's 63.30%. Such benchmarking helps identify whether Palisade Bio Inc is trading at a premium or discount relative to its financial performance.

Palisade Bio has reported a net loss of $10.6 million for Q2 2026, but it has also achieved a gross margin of 100% in the same period, indicating potential for future profitability as it moves forward with its clinical trials.